CX1739

CX1739 is a low impact enhancer of AMPA-glutamate receptors (AMPARs) . CX1739 enhances long-term potentiation dose-dependently in mouse model. CX1739 also abrogates amphetamine-induced locomotor activity. CX1739 rapidly reverses opioid-induced respiratory depression. CX1739 can be studied in research for dementia, neuropsychiatric disorders, and severe complication of opiate-induced suppression of endogenous inspiratory breathing rhythms[1].

Product Specifications

CAS Number

[1086377-48-1]

UNSPSC

12352005

Target

IGluR

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Field of Research

Neurological Disease

Purity

99.9

Smiles

O=C(C1=CC2=NON=C2C=C1)N(C)C3CCOCC3

Molecular Formula

C13H15N3O3

Molecular Weight

261.28

References & Citations

[1]Daniel Pierce Radin, et al., Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. Future Pharmacol. 2024, 4 (1), 173-187.